Farther Finance Advisors LLC Boosts Stake in Pfizer Inc. (NYSE:PFE)

Farther Finance Advisors LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 44.1% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 85,290 shares of the biopharmaceutical company's stock after acquiring an additional 26,095 shares during the period. Farther Finance Advisors LLC's holdings in Pfizer were worth $2,093,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in PFE. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the fourth quarter worth about $26,000. Clarity Asset Management Inc. bought a new stake in shares of Pfizer during the fourth quarter valued at about $27,000. Gould Capital LLC grew its position in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer during the 4th quarter worth about $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in shares of Pfizer during the fourth quarter valued at approximately $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Price Performance

Shares of PFE stock traded up $0.31 during trading hours on Thursday, reaching $24.79. The stock had a trading volume of 16,988,156 shares, compared to its average volume of 40,982,211. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The stock's fifty day simple moving average is $22.96 and its 200 day simple moving average is $24.98. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $140.94 billion, a PE ratio of 17.58, a PEG ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's revenue for the quarter was down 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.82 earnings per share. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 6.94%. Pfizer's payout ratio is 124.64%.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. UBS Group upped their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price on the stock. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.